Equity · Healthcare
ANAB
NASDAQAnaptysBio (ANAB)
The line runs 55.98 USD on 13 August through 48.42 USD on 10 November, on a scale from 40 to 70. Days the market did not trade hold the previous close, flat.
- Market cap
- 1.4B USD
- Revenue, year to Dec 2025
- 234.6M USD
- EPS, diluted, year to Dec 2025
- −0.46 USD
- 52-week range
- 33 USD – 70 USD
- Avg volume
- 33.0K
as of Nov 10, 2026
Have AnaptysBio (ANAB) insiders bought or sold shares recently?
In the 90 days to 11 Nov 2026, AnaptysBio insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 16 Dec 2025, show no open-market purchase.
Form 4, 90 days to 11 Nov 2026, newest reported trade 1 Oct 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 01 Oct 2026 | RENTON HOLLINGSDirector | Sell | 5,000 | 249K USD |
2 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 01 Oct 2026 | RENTON HOLLINGSDirector | Option exercise | 5,000 | 90K USD |
| 15 Sep 2026 | Orwin John ADirector | Option exercise | 1,300 |
Which funds hold AnaptysBio (ANAB)?
8 of the 45 institutional funds we track reported a AnaptysBio position for the quarter ended 30 Jun 2026 — a combined 146.7M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Millennium Management | Added | 807,316 | 54.5M USD | +69.8% |
| D. E. Shaw & Co. | Held (±25%) | 539,666 | 36.4M USD | −6.8% |
| Citadel Advisors | Added | 394,373 | 26.6M USD | +68.9% |
| Two Sigma Investments | Trimmed | 262,995 | 17.8M USD | −43.5% |
| Renaissance Technologies | Trimmed | 58,300 | 3.9M USD | −35.9% |
| AQR Capital Management | Added | 46,323 | 3.1M USD | +42.7% |
| Marshall Wace | Trimmed | 43,822 | 3.0M USD | −35.6% |
| Tudor Investment Corp | Added | 20,019 | 1.4M USD | +303.4% |
| Balyasny Asset Management | Exited | |||
| Fisher Asset Management | Exited |
What has been filed or recorded for AnaptysBio (ANAB)?
The filings we hold for AnaptysBio, newest first: 1 fails-to-deliver day, 4 quarterly earnings reports, 4 annual reports and 5 reported financial figures, the latest dated 05 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 05 Oct 2026 | Fails to deliver | Shares failed to deliver | 6,739 shares | 327K USD notional · 0.023% of shares out |
| 30 Jun 2026 | Annual report | FY 2026 reported | EPS 3.50 USD | Revenue $53M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −1.84 USD | Revenue $26M |
| 31 Mar 2026 | Financials | Total assets | 329.7M USD | at period end |
| 31 Mar 2026 | Financials | Total equity | 12.7M USD | at period end |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −0.44 USD | Revenue $235M |
| 31 Dec 2025 | Financials | Revenue | 234.6M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −13.2M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.46 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.52 USD | Revenue $76M |
| 30 Jun 2025 | Annual report | FY 2026 reported | EPS −2.54 USD | Revenue $50M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −1.28 USD | Revenue $28M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −4.92 USD | Revenue $91M |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −1.14 USD | Revenue $30M |
What do people ask about AnaptysBio (ANAB)?
What did AnaptysBio shares close at?48.42
AnaptysBio closed at 48.42 USD on 10 Nov 2026, up 1.01% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is AnaptysBio’s market cap?1.4B
AnaptysBio is worth 1.4B USD by market value as of 10 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is AnaptysBio’s revenue?234.6M
AnaptysBio reported revenue of 234.6M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have AnaptysBio insiders bought or sold shares recently?1 sale
In the 90 days to 11 Nov 2026, AnaptysBio insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 16 Dec 2025, show no open-market purchase. A further 2 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own AnaptysBio?8 of 45
8 of the 45 funds we track reported a AnaptysBio position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, D. E. Shaw & Co. and Citadel Advisors. See Funds
When did AnaptysBio last report earnings?3.50
AnaptysBio last reported earnings on 30 Jun 2026 for FY 2026, with EPS of 3.50 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 31 Mar 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings